Test Your Knowledge with Our Clinical Case Studies!
Clinical Chemistry 56: 482-483, 2010. First published January 7, 2010; 10.1373/clinchem.2009.138255
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2009.138255v1
56/3/482    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ladenson, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ladenson, J. H.
Related Collections
Right arrow Other Areas of Clinical Chemistry
(Clinical Chemistry. 2010;56:482-483.)
© 2010 American Association for Clinical Chemistry, Inc.

Citation Classic

Troponin I, the Story

Jack H. Ladenson1

1 Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.

Address correspondence to the author at: Department of Pathology and Immunology, Washington University School of Medicine, Box 8118, 660 S. Euclid Ave., St. Louis, MO 63110. Fax 314-454-5208; e-mail ladenson@labmed.wustl.edu.

The first 20% of the full text of this article appears below.

Featured Article: Bodor GS, Porter S, Landt Y, Ladenson JH. Development of monoclonal antibodies for an assay of cardiac troponin I and preliminary results in suspected cases of myocardial infarction. Clin Chem 1992;38:2203–14.1

In the early 1980s, David N. Dietzer and I started building a team to develop monoclonal antibodies to the isoenzymes then used for detecting cardiac damage: creatine kinase (CK)2 and lactate dehydrogenase. In the clinical laboratory, these tests, which had become widely used, entailed the use of electrophoretic procedures that took a few hours to perform. Although initially this approach was adequate, the advent of new therapies to open clotted arteries (streptokinase and tissue plasminogen activator, cleared by the US Food and Drug Administration in 1982 and 1987, respectively) placed a premium on prompt treatment. This conflict between the clinical need to treat within 4–6 h . . . [Full Text of this Article]